Previous research has shown that erianin exerts anti-tumor activity by inhibiting the MAPK/ERK and PI3K/Akt signaling pathways (Ma et al., 2023), suggesting its potential as a therapeutic agent for ATC. The gene discussed is AKT1; the disease is neoplasm.